Mirum Pharmaceuticals Inc (NASDAQ: MIRM) on Friday, plunged -3.80% from the previous trading day, before settling in for the closing price of $46.26. Within the past 52 weeks, MIRM’s price has moved between $23.14 and $48.89.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 88.90% over the past five years. The company achieved an average annual earnings per share of 58.49%. With a float of $38.28 million, this company’s outstanding shares have now reached $46.72 million.
Let’s look at the performance matrix of the company that is accounted for 264 employees. In terms of profitability, gross margin is 73.47%, operating margin of -30.44%, and the pretax margin is -31.09%.
Mirum Pharmaceuticals Inc (MIRM) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Mirum Pharmaceuticals Inc is 20.26%, while institutional ownership is 94.46%. The most recent insider transaction that took place on Nov 14 ’24, was worth 117,752. In this transaction SVP, GLOBAL CONTROLLER of this company sold 2,500 shares at a rate of $47.10, taking the stock ownership to the 2,426 shares. Before that another transaction happened on Sep 18 ’24, when Company’s Director bought 115 for $37.40, making the entire transaction worth $4,301. This insider now owns 162,308 shares in total.
Mirum Pharmaceuticals Inc (MIRM) Latest Financial update
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.63 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.22) by -0.41. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 58.49% per share during the next fiscal year.
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) Trading Performance Indicators
Mirum Pharmaceuticals Inc (MIRM) is currently performing well based on its current performance indicators. A quick ratio of 3.15 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.07, a number that is poised to hit -0.28 in the next quarter and is forecasted to reach -0.69 in one year’s time.
Technical Analysis of Mirum Pharmaceuticals Inc (MIRM)
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) saw its 5-day average volume 0.62 million, a positive change from its year-to-date volume of 0.56 million. As of the previous 9 days, the stock’s Stochastic %D was 69.95%. Additionally, its Average True Range was 2.07.
During the past 100 days, Mirum Pharmaceuticals Inc’s (MIRM) raw stochastic average was set at 73.26%, which indicates a significant increase from 59.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.83% in the past 14 days, which was lower than the 44.72% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $40.12, while its 200-day Moving Average is $33.26. Nevertheless, the first resistance level for the watch stands at $46.28 in the near term. At $48.06, the stock is likely to face the second major resistance level. The third major resistance level sits at $49.32. If the price goes on to break the first support level at $43.24, it is likely to go to the next support level at $41.97. The third support level lies at $40.19 if the price breaches the second support level.
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) Key Stats
Market capitalization of the company is 2.05 billion based on 48,005K outstanding shares. Right now, sales total 186,370 K and income totals -163,420 K. The company made 77,880 K in profit during its latest quarter, and -24,640 K in sales during its previous quarter.
